ASXRacura Presents CPACS Data at GCOS 2026
other announcement
RAC
Racura Oncology
Pharmaceuticals, Biotechnology & Life Sciences
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.
Short position
short percentage0.01%
reported shorts19.4K
shares on issue196.069M
Racura Oncology (ASX:RAC) has 0.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 19,354 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. RAC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Racura Oncology (RAC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Date of AGM & Closing Date for Director Nominations
other announcement
Appendix 3Y - Dr Daniel Tillett
director_dealing announcement
Motley FoolACCC blocks Insurance Australia Group's RAC Insurance acquisition
The ACCC has blocked IAG's takeover of RAC Insurance. The post ACCC blocks Insurance Australia Group's RAC Insurance acquisition appeared first on The Motley Fool Australia.
IAG's $1.35b acquisition of RAC Insurance blocked over competition concerns in Western Australia
Insurance Australia Group (ASX: IAG) has been dealt a major blow after the Australian Competition and Consumer Commission (ACCC) formally blocked its proposed $1.35 billion acquisition of RAC Insurance (RACI) in Western Australia, ruling the deal would substantially lessen competition in the state's motor vehicle and home insurance markets. ...
Appendix 3Y - Dr Daniel Tillett
director_dealing announcement
RC220 MYC-silencing data to be presented FCS 26 conference
other announcement
Racura Oncology Adelaide Investor Briefing
other announcement
Small CapsNotification regarding unquoted securities - RAC
other announcement
CPACS Trial Opens for RC220 Patient Enrolment in Korea
other announcement
First HARNESS-1 Patient Safely Treated with RC220
other announcement
June 2026 Quarterly Activities Report and Appendix 4C
other announcement
Google NewsRacura Oncology (ASX:RAC) Edges Higher: Could This ASX Cancer-Therapy Stock Be One to Watch? - Kalkine
Racura Oncology (ASX:RAC) Edges Higher: Could This ASX Cancer-Therapy Stock Be One to Watch? Kalkine
KalkineRacura Oncology Announces Auckland Investor Briefing and Presentation at 20th Bioshares Biotech Summit in August 2026
Racura Oncology Limited (ASX: RAC), a biopharmaceutical company in Phase 3 clinical development focused on cancer silencing therapies, has scheduled two key investor events in New Zealand for August 2026. Executive Chair Dr Peter Smith will lead a morning tea briefing for current and prospective shareholders in Auckland on 5 August 2026, followed by a presentation at the 20th Bioshares Biotech Summit in Queenstown on 7 August 2026. These occasions will provide important updates on Racura's lead ...
Bellberry Ethics Approval Activates New HARNESS Trial Sites
other announcement
Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
other announcement
Race Oncology (ASX:RAC): Oncology Stock Commands Huge Market Interest After $34.3m Raising - Kalkine
Race Oncology (ASX:RAC): Oncology Stock Commands Huge Market Interest After $34.3m Raising Kalkine
Clinical-stage biotech Racura Oncology raises $34.3m to fully fund three cancer drug trials
Clinical-stage biotechnology company Racura Oncology (ASX: RAC) has raised a total of $34.3 million over two years to fully fund three clinical trials of its lead oncology asset RC220, completing the capital raise without paying any broker or underwriter fees. The funds, accumulated since June 2024 through a combination of bonus and "piggyb...
Racura Oncology Investor Briefings Perth & Auckland
other announcement
Racura raised $34.3m to Advance Three Oncology Trials
other announcement
Kalkine ASX Spotlight: What Weighed on Race Oncology (ASX:RAC) Shares Today? - Kalkine
Kalkine ASX Spotlight: What Weighed on Race Oncology (ASX:RAC) Shares Today? Kalkine
Racura Oncology (ASX:RAC) Surges 8% as RC220 Trial Cleared to Double Dosage Level - Stocks Down Under
Racura Oncology (ASX:RAC) Surges 8% as RC220 Trial Cleared to Double Dosage Level Stocks Down Under
CPACS Trial Cleared to Escalate to Next RC220 Dose Level
other announcement